High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established. METHODS: We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke. RESULTS: The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients (13.1 percent) receiving placebo had a fatal or nonfatal stroke (5-year absolute reduction in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03; unadjusted P=0.05). The atorvastatin group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year absolute reduction in the risk of major cardiovascular events was 3.5 percent (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002). The overall mortality rate was similar, with 216 deaths in the atorvastatin group and 211 deaths in the placebo group (P=0.98), as were the rates of serious adverse events. Elevated liver enzyme values were more common in patients taking atorvastatin. CONCLUSIONS: In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke. (ClinicalTrials.gov number, NCT00147602 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the recently published Lipitor's Effect in Alzheimer's Dementia (LEADe) trial, which included 640 randomized patients with mild Alzheimer disease, intensive lipid lowering by the addition of atorvastatin (80 mg) to donepezil did not improve cognitive function over a 72-week period.464”
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [438]
In the citing paper
“Following stroke or TIA, 34 patients are at risk not only of recurrent cerebrovascular events but also of other major CV events including MI.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [34]
In the citing paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12%), MI and vascular death.422,428”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [428]
In the citing paper
“Many reports have also indicated that there is no clear relationship between the TG level and cerebrovascular disease856, 862, 863).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [862]
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis
Rankin, J. (1957) · Scottish Medical Journal · doi:10.1177/003693305700200504 · Cited by 2,506
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Iso, H., Jacobs, D. R., Wentworth, D., Neaton, J. D., Cohen, J. D., & for the MRFIT Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201405 · Cited by 1,133
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Research works printed but not linked: 1
- Waters DD, 2005, Circulation, 112, 2020
Cited by
Items 301–400 of 1,005
Discontinuation of Statin Treatment in Stroke Patients
Endres, M., & Laufs, U. (2006) · Stroke · doi:10.1161/01.str.0000240690.69406.28 · Cited by 103
Reiff, T., Stingele, R., Eckstein, H., Fraedrich, G., Jansen, O., Mudra, H. G., Mansmann, U., Hacke, W., & Ringleb, P. A. (2009) · International Journal of Stroke · doi:10.1111/j.1747-4949.2009.00290.x · Cited by 102
Hu, M., Cheung, B. M. Y., & Tomlinson, B. (2012) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098612439884 · Cited by 116
“…an increase in the risk of haemorrhagic stroke during treatment with atorvastatin 80 mg/day compared with placebo for a period of 4.9 years (2.3% versus 1.4%, p = 0.002), although the relative risk of fatal and nonfatal stroke was reduced by 16% with atorvastatin treatment [Amarenco et al. 2006].”
BackgroundInfluentialBath, P. M., Scutt, P., Blackburn, D. J., Ankolekar, S., Krishnan, K., Ballard, C., Burns, A., Mant, J., Passmore, P., Pocock, S., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0164608 · Cited by 103
Ahmadi, M., Laumeier, I., Ihl, T., Steinicke, M., Ferse, C., Endres, M., Grau, A., Hastrup, S., Poppert, H., Palm, F., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30369-2 · Cited by 106
Amarenco, P., Denison, H., Evans, S. R., Himmelmänn, A., James, S. K., Knutsson, M., Ladenvall, P., Molina, C. A., Wang, Y., Johnston, S. C., et al. (2020) · Stroke · doi:10.1161/strokeaha.120.032239 · Cited by 105
Potential Benefits and Risks Associated with the Use of Statins
Khatiwada, N., & Hong, Z. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020214 · Cited by 132
“The impact of statins on intracerebral hemorrhages (ICH) has been debated, with some studies suggesting a potential risk increase [31], while recent comprehensive research and meta-analyses did not find a clear association between statin use and ICH [93–95].”
ResultTreatment with Statins in Elderly Patients
Horodinschi, R.-N., Stănescu, A. M. A., Bratu, O. G., Stoian, A. P., Radavoi, D. G., & Diaconu, C. C. (2019) · Medicina · doi:10.3390/medicina55110721 · Cited by 134
Willey, J. Z., & Elkind, M. S. V. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.199 · Cited by 102
Primary prevention of stroke: blood pressure, lipids, and heart failure
Endres, M., Heuschmann, P. U., Laufs, U., & Hakim, A. M. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq472 · Cited by 133
Hill, M. D. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00012-6 · Cited by 118
Shah, S. J., Waters, D. D., Barter, P. J., Kastelein, J. J. P., Shepherd, J., WENGER, N. K., DeMicco, D. A., Breazna, A., & LaRosa, J. C. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.054 · Cited by 100
Holme, I., AASTVEIT, A. H., Hammar, N., Jungner, I., & Walldius, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02016.x · Cited by 106
Intracranial Atherosclerotic Disease
Yaghi, S. R., Prabhakaran, S., Khatri, P., & Liebeskind, D. S. (2019) · Stroke · doi:10.1161/strokeaha.118.024147 · Cited by 100
The role of angiogenesis in damage and recovery from ischemic stroke
Arenillas, J. F., Sobrino, T., Castillo, J., & Dávalos, A. (2007) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-007-0014-5 · Cited by 99
Management of Extracranial Carotid Artery Disease
Ooi, Y. C., & Gonzalez, N. R. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.09.001 · Cited by 111
Non-high-density lipoprotein cholesterol: current status as cardiovascular marker
Verbeek, R., Hovingh, G. K., & Boekholdt, S. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000237 · Cited by 108
Amarenco, P., Goldstein, L. B., Callahan, A., Sillesen, H. H., Hennerici, M. G., O’Neill, B. J., Rudolph, A. E., Simunovic, L., Zivin, J. A., & Welch, K. M. A. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.09.008 · Cited by 102
Post-Ischaemic Immunological Response in the Brain: Targeting Microglia in Ischaemic Stroke Therapy
Rawlinson, C., Jenkins, S. I., Thei, L., Dallas, M. L., & Chen, R. (2020) · Brain Sciences · doi:10.3390/brainsci10030159 · Cited by 104
Georgakis, M. K., & Gill, D. (2021) · Stroke · doi:10.1161/strokeaha.120.032617 · Cited by 107
Cholesterol-Lowering Interventions and Stroke
Caterina, R. D., Scarano, M., Marfisi, R., Lucisano, G., Palma, F., Tatasciore, A., & Marchioli, R. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.062 · Cited by 105
Amarenco, P. (2020) · New England Journal of Medicine · doi:10.1056/nejmcp1908837 · Cited by 103
Coutts, S. B., Hill, M. D., Campos, C. R., Choi, Y. B., Subramaniam, S., Kosior, J. C., & Demchuk, A. M. (2008) · Stroke · doi:10.1161/strokeaha.107.513234 · Cited by 109
Progression of asymptomatic carotid stenosis despite optimal medical therapy
Conrad, M. F., Baloum, V., Mukhopadhyay, S., Garg, A., Patel, V. I., & Cambria, R. P. (2013) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2013.04.002 · Cited by 105
Rahimi, K., Bhala, N., Kamphuisen, P., Emberson, J., Biere-Rafi, S., Krane, V., Robertson, M., Wikstrand, J., & McMurray, J. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001310 · Cited by 94
Clinical review: Critical care management of spontaneous intracerebral hemorrhage
Rincón, F., & Mayer, S. A. (2008) · Critical Care · doi:10.1186/cc7092 · Cited by 116
Cognition After Lowering LDL-Cholesterol With Evolocumab
Gencer, B., Mach, F., Guo, J., Im, K., Ruzza, A., Wang, H., Kurtz, C. E., Pedersen, T. R., KEECH, A. C., Ott, B. R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.039 · Cited by 100
Hodis, H. N., Collins, P., Mack, W. J., & Schierbeck, L. L. (2012) · Climacteric · doi:10.3109/13697137.2012.656401 · Cited by 107
Brott, T. G., Halperin, J. L., Abbara, S., Bacharach, J. M., Barr, J. D., Bush, R. L., Cates, C. U., Creager, M. A., Fowler, S. A., Friday, G. H., et al. (2011) · Vascular Medicine · doi:10.1177/1358863x11399328 · Cited by 98
Interventions in the management of serum lipids for preventing stroke recurrence
Manktelow, B. N., & Potter, J. F. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002091.pub2 · Cited by 107
Goldstein, L. B., Toth, P. P., Dearborn, J. L., Giugliano, R. P., Hirsh, B. J., Peña, J. M., Selim, M. H., & Woo, D. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000164 · Cited by 116
Smoking cessation and outcome after ischemic stroke or TIA
Epstein, K. A., Viscoli, C. M., Spence, J. D., Young, L. H., Inzucchi, S. E., Gorman, M., Gerstenhaber, B. J., Guarino, P., Dixit, A. K., Furie, K. L., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004524 · Cited by 104
Krychtiuk, K. A., Ahrens, I., Drexel, H., Halvorsen, S., Hassager, C., Huber, K., Kurpas, D., Niessner, A., Schiele, F., Semb, A. G., et al. (2022) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuac123 · Cited by 137
Carotid Artery Stenosis: Medical Therapy, Surgery, and Stenting
Dharmakidari, S., Bhattacharya, P. D., & Chaturvedi, S. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0786-2 · Cited by 92
Georgakis, M. K., Malik, R., Anderson, C. D., Parhofer, K. G., Hopewell, J. C., & Dichgans, M. (2019) · Brain · doi:10.1093/brain/awz413 · Cited by 95
“(Amarenco et al., 2006), especially in patients with SVS as an entry event (Goldstein et al.”
BackgroundStatin Use and Microbleeds in Patients With Spontaneous Intracerebral Hemorrhage
Haussen, D. C., Henninger, N., Kumar, S., & Selim, M. H. (2012) · Stroke · doi:10.1161/strokeaha.112.657486 · Cited by 96
Recurrent lacunar infarction following a previous lacunar stroke: a clinical study of 122 patients
Arboix, A., Font, A., Garro, C. G., García‐Eroles, L., Comes, E., & Massons, J. B. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.119776 · Cited by 91
Statins for the treatment of dementia
McGuinness, B., O'Hare, J., Craig, D., Bullock, R., Malouf, R., & Passmore, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007514.pub2 · Cited by 92
Merwick, Á., Albers, G. W., Arsava, E. M., Ay, H., Calvet, D., Coutts, S. B., Cucchiara, B. L., Demchuk, A. M., Giles, M. F., Mas, J.-L., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.001576 · Cited by 89
Anti-inflammatory approaches to ischaemic stroke prevention
Kelly, P. J., Murphy, S., Coveney, S. A., Purroy, F. F., Lemmens, R., Tsivgoulis, G. K., & Price, C. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314817 · Cited by 99
Guglielmi, V., Bellia, A., Pecchioli, S., Della‐Morte, D., Parretti, D., Cricelli, I., Medea, G., Sbraccia, P., Lauro, D., Cricelli, C. A., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.05.018 · Cited by 95
“Several major RCTs clearly demonstrated the efficacy of statin therapy with regard to the prevention of CV events in patients after acute coronary syndromes [7] stroke or TIA [8], and in patients with stable coronary artery disease [9], with a weighted average reduction in major vascular events of 24% per 1 mmol/L (38…”
BackgroundInfluentialFlint, A. C., Conell, C. A., Rao, V. A., Klingman, J. G., Sidney, S., Johnston, S. C., Hemphill, J. C., Kamel, H., Davis, S. M., & Donnan, G. A. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2124 · Cited by 88
Statins in Traumatic Brain Injury
Wible, E. F., & Laskowitz, D. T. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2009.11.003 · Cited by 88
Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke
Bigalke, B., Stellos, K., Geisler, T., Kremmer, E., Seizer, P., May, A. E., Lindemann, S., Melms, A., Luft, A. R., & Gawaz, M. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02754.x · Cited by 87
Lipid Profile Components and Risk of Ischemic Stroke: The Northern Manhattan Study (NOMAS)
Willey, J. Z., Xu, Q., Boden-Albala, B., Paik, M. C., Moon, Y. P., Sacco, R. L., & Elkind, M. S. V. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.210 · Cited by 87
Goldstein, L. B., Amarenco, P., LaMonte, M., Gilbert, S., Messig, M., Callahan, A., Hennerici, M., Sillesen, H., & Welch, K. M. A. (2008) · Stroke · doi:10.1161/strokeaha.107.513747 · Cited by 86
Effect of Statins on Intracerebral Hemorrhage Outcome and Recurrence
FitzMaurice, E., Wendell, L., Snider, R. W., Schwab, K. M., Chanderraj, R., Kinnecom, C., Nandigam, K., Rost, N. S., Viswanathan, A., Rosand, J. M., et al. (2008) · Stroke · doi:10.1161/strokeaha.107.508861 · Cited by 88
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack
Chaturvedi, S., Zivin, J. A., Breazna, A., Amarenco, P., Callahan, A., Goldstein, L. B., Hennerici, M. G., Sillesen, H. H., Rudolph, A. E., & Welch, M. A. (2008) · Neurology · doi:10.1212/01.wnl.0000327339.55844.1a · Cited by 94
Simvastatin and Disease Stabilization in Normal Tension Glaucoma: A Cohort Study
Leung, D. Y. L., Li, F. C. H., Kwong, Y. Y. Y., Tham, C. C. Y., Chi, S. C. C., & Lam, D. S. C. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.08.016 · Cited by 88
Effect of Rosuvastatin on Amnesia and Disorientation after Traumatic Brain Injury (NCT00329758)
Tapia-Pérez, J. H., Sánchez-Aguilar, M., Torres-Corzo, J. G., Gordillo‐Moscoso, A., Martínez-Pérez, P., Madeville, P., Mendoza, E. D. L. C., & Chalita-Williams, J. C. (2008) · Journal of Neurotrauma · doi:10.1089/neu.2008.0554 · Cited by 95
“Additional studies have demonstrated injury limitation and a better outcome after stroke and subarachnoid and intracerebral hemorrhage (Lynch et al., 2005; Amarenco et al., 2006; Tseng et al., 2007; Naval et al., 2008).”
Oesterle, A., & Liao, J. K. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180817155058 · Cited by 92
Zheng, S., & Yao, B. (2019) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.10.026 · Cited by 85
Boulet, J., Peña, J. M., Hulten, E. A., Neilan, T. G., Dragomir, A., Freeman, C. R., Lambert, C., Hijal, T., Nadeau, L., Brophy, J. M., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.117.005996 · Cited by 89
How I treat the antiphospholipid syndrome
Giannakopoulos, B., & Krilis, S. A. (2009) · Blood · doi:10.1182/blood-2009-05-220756 · Cited by 86
Switching statins in Norway after new reimbursement policy – a nationwide prescription study
Sakshaug, S., Furu, K., Karlstad, Ø., Rønning, M., & Skurtveit, S. O. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02907.x · Cited by 85
Kronish, I. M., Goldfinger, J. Z., Negron, R., Fei, K., Tuhrim, S., Arniella, G., & Horowitz, C. R. (2014) · Stroke · doi:10.1161/strokeaha.114.006623 · Cited by 93
Rong, S., Li, B., Chen, L., Sun, Y., Du, Y., Liu, B., Robinson, J. G., & Bao, W. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023690 · Cited by 95
Muscle- and skeletal-related side-effects of statins: tip of the iceberg?
Auer, J., Sinzinger, H. F., Franklin, B., & Berent, R. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314550804 · Cited by 94
Statin Use and Risk of Cerebral Aneurysm Rupture: A Hospital-based Case–control Study in Japan
Yoshimura, Y., Murakami, Y., Saitoh, M., Yokoi, T., Aoki, T., Miura, K., Ueshima, H., & Nozaki, K. (2013) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2013.04.022 · Cited by 84
Arboix, A., García‐Eroles, L., Oliveres, M., Targa, C., Balcells, M., & Massons, J. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-47 · Cited by 94
Bergström, L., Irewall, A.-L., Söderström, L., Ögren, J., Laurell, K., & Mooe, T. (2017) · Stroke · doi:10.1161/strokeaha.117.016815 · Cited by 90
Foley, T. R., Singh, G. D., Kokkinidis, D. G., Choy, H.-H., Pham, T. H., Amsterdam, E. A., Rutledge, J. C., Waldo, S. W., Armstrong, E. J., & Laird, J. R. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005699 · Cited by 92
Contemporary prevalence of carotid stenosis in patients presenting with ischaemic stroke
Cheng, S. F., Brown, M. M., Simister, R. J., & Richards, T. (2019) · British journal of surgery · doi:10.1002/bjs.11136 · Cited by 85
Wardlaw, J. M., Brazzelli, M. G., Miranda, H., Chappell, F. M., McNamee, P., Scotland, G., Quayyum, Z., Martin, D., Shuler, K., Sandercock, P. A., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18270 · Cited by 98
Kamel, H., Hegde, M., Johnson, D. R., Gage, B. F., & Johnston, S. C. (2010) · Stroke · doi:10.1161/strokeaha.110.582437 · Cited by 86
La Aterosclerosis como enfermedad sistémica
Lahoz, C., & Mostaza, J. M. (2007) · Revista Española de Cardiología · doi:10.1157/13099465 · Cited by 146
Meier, N., Nedeltchev, K., Brekenfeld, C., Galimanis, A., Fischer, U., Findling, O., Remonda, L., Schroth, G., Mattle, H. P., & Arnold, M. (2009) · Stroke · doi:10.1161/strokeaha.108.532473 · Cited by 88
Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease
Moon, G. J., Kim, S. J., Cho, Y. H., Ryoo, S., & Bang, O. Y. (2014) · Journal of Clinical Neurology · doi:10.3988/jcn.2014.10.2.140 · Cited by 82
Wang, N., Woodward, M., Huffman, M. D., & Rodgers, A. (2022) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008552 · Cited by 80
Association between Smoking and Uveitis
Yuen, B. G., Tham, V. M., Browne, E. N., Weinrib, R., Borkar, D. S., Parker, J. V., Uchida, A., Vinoya, A. C., & Acharya, N. R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.02.034 · Cited by 86
Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-9-200911030-00144 · Cited by 79
Atorvastatin: Pharmacological Characteristics and Lipid-Lowering Effects
Poli, A. (2007) · Drugs · doi:10.2165/00003495-200767001-00002 · Cited by 85
Statin myopathy: a review of recent progress
Mammen, A. L., & Amato, A. A. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32833f0fc7 · Cited by 79
Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007
(ESH), G. D. T. P. E. T. D. L. H. A. D. L. S. E. D. H., & de Cardiología, D. L. S. E. (2007) · Revista Española de Cardiología · doi:10.1157/13109650 · Cited by 100
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
Lochhead, J. J., Ronaldson, P. T., & Davis, T. P. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116186 · Cited by 95
Recomendaciones preventivas cardiovasculares
Galán, Á. M. M., Cuixart, C. B., Álvarez, F. V., Pérez, J. N., Lobos-Bejarano, J. M., Sánchez-Pinilla, R. O., Rioboó, E. M., Banegas, J. R. B., Orozco‐Beltrán, D., & Gil-Guillén, V. F. (2012) · Atención Primaria · doi:10.1016/s0212-6567(12)70010-0 · Cited by 85
Statins: an essential component in the management of carotid artery disease
Paraskevas, K. I., Hamilton, G., & Mikhailidis, D. P. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.03.035 · Cited by 77
Deficiency of 25-Hydroxyvitamin D and Dyslipidemia in Indian Subjects
Chaudhuri, J. R., Mridula, K. R., Anamika, A., Boddu, D. B., Mısra, P. K., Lingaiah, A., Balaraju, B., & Bandaru, V. S. (2013) · Journal of Lipids · doi:10.1155/2013/623420 · Cited by 82
Beheshti, S. O., Madsen, C. M., Varbo, A., Benn, M., & Nordestgaard, B. G. (2018) · Circulation · doi:10.1161/circulationaha.118.033470 · Cited by 83
Prevention and management of stroke in very elderly patients
Sanossian, N., & Ovbiagele, B. I. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70259-5 · Cited by 83
Amarenco, P., Goldstein, L. B., Messig, M., O’Neill, B. J., Callahan, A., Sillesen, H. H., Hennerici, M. G., Zivin, J. A., & Welch, K. M. A. (2009) · Stroke · doi:10.1161/strokeaha.108.546135 · Cited by 80
Stramba‐Badiale, M. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq094 · Cited by 87
Benefits of statin therapy and compliance in high risk cardiovascular patients
DEEDWANIA, P. C., & Lardizabal (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s9474 · Cited by 81
Howard, G., Cushman, M., Howard, V. J., D, B. M. K. M., Kleindorfer, D., Moy, C. S., Switzer, J., & Woo, D. (2013) · Stroke · doi:10.1161/strokeaha.111.000529 · Cited by 87
Bennett, K. M., Scarborough, J. E., & Shortell, C. K. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2014.05.100 · Cited by 76
Tuttolomondo, A., Raimondo, D. D., Pecoraro, R., Maida, C. D., Arnao, V., Corte, V. D., Simonetta, I., Corpora, F., Bona, D. D., Maugeri, R., et al. (2016) · Medicine · doi:10.1097/md.0000000000003186 · Cited by 78
Statin Therapy for Stroke Prevention
Nassief, A. M., & Marsh, J. D. (2008) · Stroke · doi:10.1161/strokeaha.107.501361 · Cited by 86
Effects of Statin Intensity and Adherence on the Long-Term Prognosis After Acute Ischemic Stroke
Kim, J., Lee, H. S., Nam, C. M., & Heo, J. H. (2017) · Stroke · doi:10.1161/strokeaha.117.018140 · Cited by 82
Intracranial Aneurysm as a Macrophage-mediated Inflammatory Disease
Shimizu, K., Kushamae, M., Mizutani, T., & Aoki, T. (2019) · Neurologia medico-chirurgica · doi:10.2176/nmc.st.2018-0326 · Cited by 75
Waters, D. D., LaRosa, J. C., Barter, P. J., Fruchart, J., Gotto, A. M., Carter, R., Breazna, A., Kastelein, J. J. P., & Grundy, S. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.041 · Cited by 75
Nanotechnology for the Detection and Therapy of Stroke
Kyle, S., & Saha, S. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201400009 · Cited by 81
Hyperlipidemia in Stroke Pathobiology and Therapy: Insights and Perspectives
Menet, R., Bernard, M., & ElAli, A. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00488 · Cited by 88
Prior Statin Use Reduces Mortality in Intracerebral Hemorrhage
Naval, N. S., Abdelhak, T. A., Zeballos, P., Urrunaga, N. H., Mirski, M. A., & Carhuapoma, J. R. (2007) · Neurocritical Care · doi:10.1007/s12028-007-0080-2 · Cited by 77
van den Hoek, H. L., Bos, W. J. W., de Boer, A., & van de Garde, E. M. W. (2011) · BMJ · doi:10.1136/bmj.d7281 · Cited by 78
ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting
Bates, E., Babb, C. J. D., Casey, D. E., Cates, C. U., Duckwiler, G., Feldman, T. E., Gray, W. A., Ouriel, K., Peterson, E. D., Rosenfield, K., et al. (2007) · Vascular Medicine · doi:10.1177/1358863x06076103 · Cited by 79
Montaner, J., Bustamante, A., García‐Matas, S., Martínez-Zabaleta, M., Jiménez, C., de la Torre, J., Rubio, F. R., Segura, T., Masjuán, J., Cánovas, D., et al. (2016) · Stroke · doi:10.1161/strokeaha.116.014600 · Cited by 82
Fibrinogen depleting agents for acute ischaemic stroke
Hao, Z., Liu, M., Counsell, C. E., Wardlaw, J. M., Lin, S., & Zhao, X. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000091.pub2 · Cited by 74
Management of intracerebral hemorrhage
Gurol, M. E., & Greenberg, S. M. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0050-y · Cited by 72
Leker, R. R., Khoury, S. T., Raphaeli, G., Shwartz, R., Eichel, R., & Tanné, D. (2009) · Stroke · doi:10.1161/strokeaha.108.546259 · Cited by 82
Metadata
- Authors
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Affiliations
- Université Paris Diderot (FR)
- Corresponding author
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-08-10
- Volume
- 355
- Issue
- 6
- Pages
- 549-559
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1546258268
- Cited by
- 2,887
- References
- 21
- Citations by year
- 2026: 86 · 2025: 96 · 2024: 119 · 2023: 112 · 2022: 135 · 2021: 134 · 2020: 139 · 2019: 140 · 2018: 129 · 2017: 132 · 2016: 139 · 2015: 125 · 2014: 142 · 2013: 160 · 2012: 149
- FWCI
- 200.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Eisai
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Keywords
- atorvastatin, high-intensity statin therapy, stroke, transient ischemic attack, secondary stroke prevention, LDL cholesterol lowering, hemorrhagic stroke, ischemic stroke, cardiovascular events, elevated liver enzymes, lipid-lowering therapy, mortality, serious adverse events
- MeSH terms
- Atorvastatin, Adult, Cardiovascular Diseases, Cerebral Hemorrhage, Cerebral Infarction, Ischemic Attack, Transient, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Pyrroles, Risk, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.